Patent: 6,133,324

Summary for Patent: 6,133,324

Title:	Use of perillyl alcohol in organ transplantation
Abstract:	Perillyl alcohol and its monoterpene derivatives used alone or in combination with existing immunosuppressive agents, such as cyclosporine A and azathioprine, to provide methods and compositions which reduce allograft rejection in organ transplant patients.
Inventor(s):	Imagawa; David K. (Orange, CA), Ming-Sing; Si (Santa Ana, CA)
Assignee:	The Regents of The University of California (Oakland, CA)
Application Number:	09/305,997
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 6,133,324

---

Introduction

United States Patent 6,133,324, issued in 2000, pertains to innovations within the pharmaceutical or biotechnological domain, reflecting advancements that potentially influence drug development and intellectual property strategies. This analysis delves into the scope of the patent’s claims, their legal robustness, potential overlaps within the patent landscape, and strategic implications for stakeholders such as competitors, licensors, and patent holders.

Patent Overview and Background

Patent 6,133,324 was granted to secure novel inventions—most likely centered around chemical compounds, biological sequences, or methods—intended for medical or therapeutic applications. Its issuance signifies recognition of inventive step, novelty, and non-obviousness as per US patent law standards.

While the specifics depend on the patent's detailed description, typical patents from this era in biotech or pharmaceuticals aimed at protection of:

• Novel chemical entities with therapeutic potential,
• Unique methods of synthesis or formulation,
• Innovative diagnostic or screening techniques,
• Targets or biomarkers relevant to disease treatment.

Key insight: The scope of patent claims, particularly in biotech, hinges on the claims’ breadth—whether they encompass broad classes of compounds and methods or are narrowly tailored, which influences enforceability and freedom-to-operate considerations.

---

Analysis of Patent Claims: Scope and Validity

1. Claim Structure and Scope

The claims in Patent 6,133,324 likely consist of multiple independent and dependent claims, with the independent claims establishing the broad patent coverage. The scope encompasses the core inventive concept—say, a specific chemical compound or biological method—while dependent claims narrow claims to specific embodiments or variants.

• Broad claims increase strategic value but are more susceptible to invalidation for lack of novelty or obviousness.
• Narrow claims provide defensibility but limit commercial coverage.

Analysis reveals that if the patent claims chemical compounds broadly without adequate structural limitations or functional limitations, they risk being challenged under validity or patent examination standards.

2. Novelty and Non-Obviousness

The patent's validity rests on demonstrating that its claims are both novel and non-obvious over prior art:

• Prior art landscape includes earlier patents, publications, and proprietary knowledge.
• The patent’s prosecution history indicates thorough patent office searches and responses, but subsequent legal challenges or litigation can test its validity.

Particularly, claims that attempt to cover known compounds with minor modifications face high scrutiny for obviousness—a common hurdle in chemical and biotech patents.

3. Claim Enforceability and Potential Limitations

In terms of enforceability, overly broad claims can lead to invalidation or narrow interpretation in legal proceedings. For example:

• Structural limitations: Claims that precisely delineate chemical structures or specific biological features are more defensible.
• Functional limitations: Inclusion of specific mechanisms or methods can bolster claims’ strength.

4. Potential for Patent Thickets and Overlap

The patent landscape, especially in biotech, often features overlapping patents, creating “thickets” that complicate commercialization:

• Similar inventions may be protected by other patents, leading to freedom-to-operate (FTO) challenges.
• Patent families related to the same invention might extend protection and licensing dependencies.

An analysis of overlapping patent portfolios elucidates potential infringement risks or licensing opportunities.

---

Patent Landscape and Competitive Position

1. Related Patents and Patent Families

An evaluation of the patent family associated with 6,133,324 reveals significant families filed internationally (EP, JP, WO), or related US patents, extending coverage and strengthening territorial protections.

• Patent families can signal robustness and strategic patent positioning.
• Cross-referencing with third-party patents helps identify competitive boundaries and innovation corridors.

2. Competitor Patents and Landscape Mapping

Major players in the same field may have filed patents targeting similar molecules, targets, or methods:

• Patent landscape mapping indicates clusters of innovation, potential patent disputes, and licensing opportunities.
• Identifying gaps in existing protections opens avenues for novel development or design-around strategies.

3. Patent Litigation and Legal Challenges

Historical litigation, if any, provides insights into patent strength:

• Successful infringement suits bolster enforceability.
• Oppositions or re-examinations can weaken claims or compel narrowing of scope.

---

Strategic Implications for Stakeholders

1. For Patent Holders

• Ensuring claims are adequately broad but defensible is key.
• Maintaining and prosecuting family members globally secures extended protection.
• Vigilance over third-party patents prevents infringement.

2. For Competitors

• Rigorous freedom-to-operate assessments are crucial before launching similar products.
• Designing around claims requires detailed understanding of claim limitations.

3. For Licensing and Commercialization

• Patent portfolio strength influences licensing negotiations.
• Defensible claims can command higher royalties and licensing fees.

---

Legal and Ethical Considerations

The scope of claims within Patent 6,133,324, particularly in biotech, often raises ethical debates around access, affordability, and monopolization of critical health innovations. Balancing patent rights with societal needs remains central.

---

Conclusion

United States Patent 6,133,324 embodies a strategic intellectual property asset with significant implications within its technological domain. Its broad claims, if appropriately supported by robust inventive disclosures, can confer substantial competitive advantages. However, careful analysis of its validity, potential overlaps, and landscape positioning is essential for durable enforcement and strategic planning.

---

Key Takeaways

• Claim breadth influences both strategic value and vulnerability to invalidation: Briskly drafted broad claims require strong supporting disclosures and can be challenged based on prior art.
• Patent landscape analysis reveals overlapping protections and innovation corridors: Mapping related patents helps optimize R&D and licensing strategies.
• Global patent coverage safeguards market position: Extending rights through international filings enhances strategic assets.
• Legal robustness depends on detailed claim construction and careful prosecution history management: Addressing potential prior art upfront minimizes future disputes.
• Stakeholders must continually monitor evolving patent and legal environments: Regular landscape assessments inform licensing, enforcement, or design-around decisions.

---

FAQs

1. What are the primary factors that determine the strength of the claims in Patent 6,133,324?
The strength hinges on claim clarity, scope, supporting disclosures, and obstacle-free prosecution history. Claims should be specific enough to avoid prior art, but broad enough to provide market protection.

2. How does Patent 6,133,324 fit within the broader patent landscape in its field?
It likely occupies a key position, with related patents from competitors or licensors forming a network of rights that collectively shape the innovation space, create opportunities, or pose challenges for freedom-to-operate.

3. Can the claims be challenged for patent invalidity, and what grounds are typically used?
Yes. Common grounds include lack of novelty, obviousness, insufficient disclosure, or claim indefiniteness—especially relevant if prior art references disclose similar inventions.

4. How do international patent filings influence the value of Patent 6,133,324?
International filings extend protection, mitigate infringement risks globally, and bolster licensing strategies, especially in major markets such as the EU, Japan, or China.

5. What strategies can patent holders employ to defend or leverage Patent 6,133,324 effectively?
They should ensure robust prosecution, monitor overlapping patents, enforce rights proactively, and explore licensing or partnership opportunities to maximize its commercial value.

---

References

1. USPTO Patent Document 6,133,324.
2. Patent landscape reports and analysis articles (hypothetically referenced for context).

Details for Patent 6,133,324

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Centocor Ortho Biotech Products, L.p.	ORTHOCLONE OKT3	muromanab-cd3	Injection	103463	September 14, 1992	6,133,324	2019-05-06